The Company recently reported positive results from its Phase IIb dose-ranging clinical trial for its lead product candidate, PAC-113, a novel anti-fungal drug. The Phase IIb study, which involved over 200 seropositive HIV patients, demonstrated that PAC-113 efficacy profile compares favorably to the efficacy of Nystatin, a current standard of care for topical treatment of oral Candidiasis. Pacgen will begin preparing for Phase III development and seek collaboration and commercialization partner for PAC-113.
Pacgen also has an early stage
research program. The most advanced of three candidates
is a peptide therapeutic, PAC-G31P, which is currently being
investigated in preclinical studies for its potential to
treat inflammatory disease.